ROCO
3218
Market cap370mUSD
Nov 12, Last price
145.00TWD
Name
Universal Vision Biotechnology Co Ltd
Chart & Performance
P/E
10.89
P/S
2.74
EPS
13.32
Div Yield, %
4.83%
Shrs. gr., 5y
—
Rev. gr., 5y
24.41%
Revenues
4.23b
+3.58%
Net income
1.06b
+1.88%
CFO
1.67b
+7.63%
Dividend
Apr 18, 20247 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. Its clinic provides laser vision correction surgery for myopia, hyperopia, astigmatism, and presbyopia; intraocular lens surgery for presbyopia and cataract; phacoemulsification and femtosecond laser for cataract surgery; and myopia control services, as well as services for dry eyes, retinal detachment, macular degeneration, strabismus, amblyopia, and other eye diseases. The company also offers vision products and services, including a range of eyeglass frames, multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, regular/colored contact lenses, eye supplements, etc.; eye plastic and micro cosmetic surgery; and customized aesthetic medicine consulting. In addition, it engages in the provision of optometric, hospital management, and technical consultancy services; and sales and leasing of medical devices. Universal Vision Biotechnology Co., Ltd. was founded in 1992 and is based in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||